v3.26.1
Other Significant Agreements - Paragon Agreement (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 12, 2024
USD ($)
Jun. 30, 2026
USD ($)
shares
Nov. 30, 2023
USD ($)
Nov. 30, 2022
USD ($)
Item
shares
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
shares
Other Significant Agreements Paragon Option Agreement                            
Research and development [1]         $ 67,301,000 $ 55,703,000           $ 128,120,000 $ 102,090,000  
Issued total common units (in shares) | shares   75,611,894     75,611,894             75,611,894   69,038,943
Option Agreement                            
Other Significant Agreements Paragon Option Agreement                            
Payments due upon exercise of option     $ 0                      
Paragon IL13 License Agreement | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Nomination fee paid                     $ 2,000,000      
Paragon Therapeutics, Inc | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Research and development         $ 200,000 100,000           $ 900,000 100,000  
Paragon Therapeutics, Inc | Option and License Agreements | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Research and development         200,000 $ 100,000           900,000 $ 100,000  
Paragon Therapeutics, Inc | Option Agreement                            
Other Significant Agreements Paragon Option Agreement                            
Payments due upon exercise of option       $ 0                    
Termination period of agreement     30 days                      
Period of material breach     30 days                      
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice     30 days                      
Payment of non-refundable fees                   $ 2,000,000        
Paragon Therapeutics, Inc | Option Agreement | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Number of selected targets initially included under the agreement | Item       2                    
Upfront cash amount paid       $ 1,300,000                    
Issued common units (in shares) | shares       1,250,000                    
Non-refundable fee     $ 2,000,000 $ 500,000                    
Paragon Therapeutics, Inc | Option Agreement | Minimum | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Fees to be paid for CMC activities if agreed to perform   $ 1,300,000                        
Paragon Therapeutics, Inc | Option Agreement | Maximum Revenue Percentage | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Issued total common units (in shares) | shares       3,750,000                    
Fees to be paid for CMC activities if agreed to perform   2,000,000                        
Paragon Therapeutics, Inc | Paragon IL13 License Agreement                            
Other Significant Agreements Paragon Option Agreement                            
Expiration period of commercial sale       12 years                    
Termination period of agreement       60 days                    
Period of material breach       90 days                    
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice       30 days                    
Paragon Therapeutics, Inc | Paragon IL13 License Agreement | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Maximum amount of achievement of development and clinical mile stones       $ 3,000,000                    
Nomination fee paid       1,000,000     $ 5,000,000 $ 2,000,000 $ 1,000,000 $ 2,000,000 $ 1,000,000      
Milestone payment of trial payable       $ 2,000,000                    
Paragon Therapeutics, Inc | Paragon IL31R License Agreement | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Maximum amount of achievement of development and clinical mile stones   23,250,000     $ 23,250,000             $ 23,250,000    
Milestone payment of trial payable   $ 5,250,000                        
Paragon Therapeutics, Inc | TSLP License Agreement | Related party                            
Other Significant Agreements Paragon Option Agreement                            
Maximum amount of achievement of development and clinical mile stones $ 28,000,000                          
Nomination fee paid 3,000,000           $ 3,000,000              
Milestone payment of trial payable $ 5,000,000                          
[1] Includes related party amounts of $215 and $855 for the three and six months ended June 30, 2026, respectively, and $98 and $130 for the three and six months ended June 30, 2025, respectively.